T1	No-of-participants 363 366	129
T2	ethinicity 367 374	Chinese
T3	ethinicity 419 428	Hong Kong
T4	eligibility 434 546	equired adjuvant tamoxifen for breast cancer after the completion of postoperative radiotherapy and chemotherapy
T5	intervention 20 64	levonorgestrel-releasing intrauterine system
T6	control 693 706	control group
T7	outcome-Measure 712 726	uterine cavity
T8	No-of-participants 1026 1028	94
T9	duration 1045 1051	5-year
T10	outcome 1106 1139	occurrence of submucosal fibroids
T13	outcome 1329 1355	de novo endometrial polyps
T14	outcome 1521 1550	breast cancer recurrence rate
T17	outcome 1591 1612	cancer-related deaths
T18	outcome 1178 1201	endometrial hyperplasia
T19	intervention-value 1208 1209	0
T11	intervention-value 1141 1142	1
T23	intervention-value 1144 1148	1.8%
T12	control-value 1164 1165	2
T24	control-value 1167 1171	3.4%
T15	control-value 1552 1554	10
T25	control-value 1556 1561	17.2%
T16	intervention-value 1577 1578	6
T26	intervention-value 1580 1585	10.0%
T21	control-value 1614 1615	6
T27	control-value 1617 1622	10.3%
T22	intervention-value 1638 1639	5
T28	intervention-value 1641 1645	8.3%
